Seattle-based Targeted Genetics has cut 26 staffers and plans to concentrate its development efforts on a new treatment for inflammatory arthritis. CEO H. Stewart Parker said the strategy was designed to give the biotech a better chance of success. Targeted Genetics is working to avoid being de-listed from NASDAQ.
- read this report from the Seattle Post-Intelligencer